|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2003-4-7
|
|
pubmed:abstractText |
To study whether all-trans retinoic acid (ATRA) combined with arsenic trioxide (As(2)O(3)) in acute promyelocytic leukemia (APL) treatment could further improve the clinical and molecular remission rate.
|
|
pubmed:language |
chi
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0253-2727
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
24
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
25-7
|
|
pubmed:meshHeading |
pubmed-meshheading:12679006-Adolescent,
pubmed-meshheading:12679006-Adult,
pubmed-meshheading:12679006-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:12679006-Arsenicals,
pubmed-meshheading:12679006-Disease-Free Survival,
pubmed-meshheading:12679006-Female,
pubmed-meshheading:12679006-Follow-Up Studies,
pubmed-meshheading:12679006-Gene Expression,
pubmed-meshheading:12679006-Humans,
pubmed-meshheading:12679006-Leukemia, Promyelocytic, Acute,
pubmed-meshheading:12679006-Male,
pubmed-meshheading:12679006-Middle Aged,
pubmed-meshheading:12679006-Oncogene Proteins, Fusion,
pubmed-meshheading:12679006-Oxides,
pubmed-meshheading:12679006-Remission Induction,
pubmed-meshheading:12679006-Time Factors,
pubmed-meshheading:12679006-Treatment Outcome,
pubmed-meshheading:12679006-Tretinoin
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
[Clinical observation of the short-term efficacy of the treatment with combination of all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) in newly diagnosed acute promyelocytic leukemia (APL)].
|
|
pubmed:affiliation |
Department of Hematology, Ruijin Hospital, Shanghai Second Medical University, Shanghai 200025, China.
|
|
pubmed:publicationType |
Journal Article,
English Abstract
|
